ABIOMED Stock News

Abiomed (ABMD) delivered earnings and revenue surprises of 23.81% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.

A strategist says there's a key element missing before the Fed will pivot.

ABIOMED Inc (NASDAQ: ABMD) opened about 50% up on Tuesday after Johnson & Johnson (NYSE: JNJ) said it will buy the heart pump maker for $16.6 billion.

Abiomed (ABMD) delivered earnings and revenue surprises of 23.81% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

J&J's cardiovascular devices business will benefit from the $16.6 billion deal to acquire Abiomed. The deal comes at a time when J&J is spinning off its consumer health business.

Johnson & Johnson is set to buy medical device company Abiomed in cash for $380 per share. CNBC's 'Squawk Box' team breaks down the deal.

The pharmaceutical giant will buy the heart-pump maker for $380 a share.

Shares of Abiomed Inc. ABMD, -2.32% rocketed 48.8% toward a 14-month high in premarket trading Tuesday, after the provider of medical technology that supports circulation and oxygenation agreed to acq

MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, CTLT, ECL, ABMD, HSIC and IDXX are placed ahead of their earnings releases.

Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.

Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.

Nevro, Masimo, Abiomed and Glaukos are part of the Zacks top Analyst Blog.

Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.

Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.